ASD Insight Test is a Critical Step in Redefining Autism as a Biologically Measurable Condition
NeuroQure, a leader in neurological diagnostics, has introduced ASD Insight, the first test designed to identify autism risk at birth. This innovative approach marks a significant step toward understanding autism as a biologically measurable condition rather than one diagnosed solely through observation. ASD Insight gives clinicians and families the ability to detect risk early, enabling targeted interventions during critical stages of neurodevelopment and improving long-term outcomes for children.
Health Technology Insights: Solventum Wins Diamond HIRC Badge for Top Supply Chain Strength
David Justus, Founder and CEO of NeuroQure, emphasized the importance of early detection, stating that identifying autism risk early allows for timely treatment, which can dramatically improve cognitive, social, and behavioral development. Despite advances in research, the average age of autism diagnosis in the United States remains around five years, often missing crucial windows for intervention.
Dr. John Jay Gargus, MD, PhD, Founding Scientist and Chief Scientific Officer at NeuroQure and Professor Emeritus at the University of California, Irvine, explained that ASD Insight builds on decades of his research into calcium signaling and mitochondrial dysfunction in autism. Using an advanced optical patch clamp technique, the test detects mitochondrial and neurotransmitter dysfunctions linked to autism. NeuroQure’s CLIA-certified laboratory analyzes skin biopsy samples and delivers risk assessments to clinicians within weeks.
Health Technology Insights: OrthAlign Expands Lantern Hip Platform for Posterior THA
Dr. Gargus noted that dysregulated calcium signaling appears to be a central pathway affecting multiple autism genotypes. ASD Insight represents the first clinical tool to translate this research into practice, identifying cellular and metabolic abnormalities before behavioral symptoms appear. Early identification allows families and healthcare providers to initiate intervention strategies as early as six months of age, a time when therapy can be most effective.
Studies show that children who start treatment by age two achieve meaningful improvements in cognition and social skills, with many reaching independent living and workforce participation later in life. Delayed diagnosis, by contrast, often results in higher long-term medical costs and increased dependence.
Justus reiterated that the new test empowers families with critical knowledge about their child’s development from birth. He emphasized that early diagnosis opens the door to earlier treatment, giving children a better chance at reaching their full potential and improving their lifelong health and quality of life.
Health Technology Insights: Ferronova Raises $6 Million to Boost Image-Guided Cancer Surgery
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
